Skip to main content

Table 7 Effect of duration of treatment with aspirin on the risk of UGIB and perforation among current users as compared to non-use by aspirin dose

From: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

  All cases Controls Adjusted RR*
  (N=2,105) (N=11,500) (95%CI)
Daily dose as instructed/    
Days of treatment/    
   75 mg    
1-60 17 32 3.2 (1.7-6.1)
61-180 20 37 2.9 (1.6-5.2)
181-730 53 166 1.7 (1.2-2.5)
>731 51 185 1.7 (1.3-4.6)
   150 mg    
1-60 13 11 6.6 (2.7-15.9)
61-180 11 23 2.7 (1.2-6.0)
181-730 26 83 2.0 (1.2-3.2)
>730 34 128 1.5 (1.0-2.2)
   300 + mg    
1-60 10 9 6.0 (2.2-16.2)
61-180 3 11 1.9 (0.5-7.1)
181-730 17 37 2.6 (1.4-4.9)
>730 32 115 1.7 (1.1-2.6)
  1. *Adjusted for sex, age, calendar year, antecedents of gastrointestinal disorders, smoking status, alcohol consumption and use of NSAIDs, anticoagulants, steroids, SSRIs and paracetamol.